ArticleClinical kidney journal2026
Combined statin and fenofibrate therapy and cardiorenal outcomes in patients with CKD, dyslipidemia, and ischemic heart disease.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adults with non-dialysis-dependent chronic kidney disease (CKD), ischemic heart disease (IHD), and hypertriglyceridemia are at high cardiorenal risk; whether starting fenofibrate together with statin therapy is effective and safe in this population is uncertain. Methods: In a multicenter retrospective cohort study emulating a target trial in the TriNetX Global Collaborative Network (2018-2024), 112 003 (28.5%) of 392 969 statin initiators with CKD and hypertriglyceridemia had IHD. Those without dialysis dependence were assigned to statin-fenofibrate combination therapy or statin monotherapy according to fenofibrate initiation within 3 months of the first statin prescription. The main outcomes were expanded major adverse cardiovascular events (MACEs) (acute myocardial infarction, stroke, heart failure, cardiac arrest, or all-cause death) and end-stage kidney disease (ESKD) necessitating dialysis. Propensity score matching yielded 3191 pairs. Cox models estimated hazard ratios (HRs). Results: Median follow-up was 881 days with combination therapy and 925 days with statin monotherapy. Combination therapy was associated with lower risks of MACE [1472 [46.1%] vs 1576 [49.4%] events; HR, 0.93; 95% confidence interval (CI), 0.86-0.99] and ESKD necessitating dialysis (264 [8.3%] vs 335 [10.5%]; HR, 0.79; 95% CI, 0.67-0.92). Risks of all-cause mortality (377 vs. 375), acute myocardial infarction (537 vs. 570), heart failure (1059 vs. 1134), stroke (310 vs. 312), acute kidney injury (825 vs. 840), and coded safety events were not significantly different between groups. Conclusions: Among selected adults with non-dialysis-dependent CKD, hypertriglyceridemia, and IHD, statin-fenofibrate combination therapy was associated with lower risks of MACE and of ESKD necessitating dialysis, without a significant increase in coded safety events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.